PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer

PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer

Abstract Chemoresistance remains the primary challenge of clinical treatment of gastric cancer (GC), making the biomarkers of chemoresistance crucial for treatment decision. Our previous study has reported that p21-actived kinase 6 (PAK6) is a prognostic factor for selecting which patients with GC a...

Full description

Bibliographic Details
Main Authors: Weicai Huang, Zhen Han, Zepang Sun, Hao Feng, Liying Zhao, Qingyu Yuan, Chuanli Chen, Shitong Yu, Yanfeng Hu, Jiang Yu, Hao Liu, Guoxin Li, Yuming Jiang
Format: Article
Language:English
Published: Nature Publishing Group 2022-07-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-05118-8

Internet

https://doi.org/10.1038/s41419-022-05118-8

Similar Items